Asian Spectator

ACN Newswire Business

Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the Alzheimer's Association International Conference (AAIC) 2020

  • Written by ACN Newswire - Press Releases

Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the Alzheimer's Association International Conference (AAIC) 2020

TOKYO, Jul 22, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will conduct a total of 9 presentations, including the latest data of the investigational anti-amyloid beta (Aβ) protofibril antibody BAN2401, at the Alzheimer's Association International Conference (AAIC) to be held virtually from July 27 to 31, 2020.Regarding BAN2401, the clinical study design of the newly initiated Phase III clinical study AHEAD 3-45 for preclinical Alzheimer's disease (AD) patients will be presented orally. The latest data on the analysis of occurrence of amyloid-related imaging abnormalities-edema (ARIA-E) and brain Aβ levels from the ongoing open-label extension study (OLE) portion of the Phase II study (Study 201) will also be presented.The safety and efficacy results from a Phase II clinical study on lemborexant (orexin receptor antagonist) targeting Irregular Sleep Wake Rhythm Disorder (ISWRD) associated with AD will be presented.Eisai is also planning to host a satellite symposium "Development of the A/T/N/x Classification System for Different Context of Use Across the Alzheimer's Disease Continuum: State-of-the-Art and future Perspectives for Clinical Practice and Therapy Development". Dr. Jeffrey Cummings (Chair), Dr. Clifford Jack, and Dr. Kaj Blennow, three renowned AD researchers and clinicians, will provide a comprehensive overview of the significance and conceptual framework of the A/T/N/x categorization system in the AD continuum. Finally, they will hold a discussion on the future outlook of this classification system for Alzheimer's pharmacological trials and clinical practice.Regarding aducanumab, for which submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval as an Alzheimer's Disease treatment was completed in July 2020, Biogen Inc. (Headquarters: Cambridge, Massachusetts, United States) will conduct an oral presentation of the previously publicized topline results of Phase III studies EMERGE and ENGAGE. This data has been shared at prior medical congresses.BAN2401 and aducanumab are being jointly developed by Eisai and Biogen Inc.Eisai aims to realize the prevention and cure of dementia through a multi-dimensional and holistic approach with a foundation of over 35 years of experience of drug discovery activities in the area of AD and dementia. Eisai strives to create innovative medicines as soon as possible to further contribute to addressing the unmet medical needs of, as well as increasing the benefits provided to, those living with the disease and their families.

About Eisai

Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Contact:Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Barilla Foundation and Food Tank announce the event: “Resettin...

PARMA, Italy, Nov. 27, 2020 /PRNewswire-AsiaNet / -- "We need a positive movement to accelerate, empower, refine, and design a more sustainable future, and raise awareness in people - compan...

Nubian Completes Acquisition of Yandoit Advanced Gold Project ...

TORONTO, Nov. 28, 2020 /PRNewswire-AsiaNet/ -- Nubian Resources Ltd. (TSXV: NBR) ("Nubian" or the "Company") is pleased to announce that further to the Company's press release of November 23...

Vuse announces global partnership with award-winning band Rudi...

LONDON, Nov. 28, 2020 /PRNewswire-AsiaNet / -- Vuse has partnered with award-winning band Rudimental on a series of initiatives that promise to electrify creativity and inspire audiences wor...

Deriv.com Acquires the Quill5 Building in Cyberjaya, Malaysia

CYBERJAYA, Malaysia, Nov. 27, 2020 /PRNewswire-AsiaNet/ -- Deriv Services Sdn Bhd, Deriv.com's Malaysian operational headquarters, announced that it has entered into a sale and purchase agre...

VUNO Boasts its AI Solutions and Research Results at RSNA 2020

SEOUL, Nov. 28, 2020 /PRNewswire-AsiaNet/ -- South Korean artificial intelligence (AI) developer VUNO Inc. announced that it will join the Radiological Society of North America 2020 (RSNA 20...

Five nations unite to launch the Digital Cooperation Organizat...

RIYADH, Saudi Arabia, Nov. 27, 2020 /PRNewswire-AsiaNet/ -- Senior government officials from several nations patronized the launch of the Digital Cooperation Organization (DCO) Thursday &nda...

Magazine

Australian startup CareApp receives funding injection to expand app

Australian based startup CareApp has recently raised over $500,000 in funding including $250,000 provided by the South Australian State Government to rapidly expand and scale up their smartphone...

Shaparency launches to enable businesses to go fully digital

New venture developed for post-Covid-19 corporate landscape London-based start-up Shaparency, which has been established in response to the business conditions resulting from Covid-19, announces ...

Specops Significant Cyber Attacks

The prevalence and severity of cyber attacks are increasing at an alarming rate every year. So much so, that statistics from Cybersecurity Ventures estimate that cybercrime will cost the global ...

Writers Wanted



News Co Media Group

Content & Technology Connecting Global Audiences

More Information - Less Opinion